MXPA02002138A - Inhibidores triciclicos de poli (adp-ribosa) polimerasas. - Google Patents

Inhibidores triciclicos de poli (adp-ribosa) polimerasas.

Info

Publication number
MXPA02002138A
MXPA02002138A MXPA02002138A MXPA02002138A MXPA02002138A MX PA02002138 A MXPA02002138 A MX PA02002138A MX PA02002138 A MXPA02002138 A MX PA02002138A MX PA02002138 A MXPA02002138 A MX PA02002138A MX PA02002138 A MXPA02002138 A MX PA02002138A
Authority
MX
Mexico
Prior art keywords
polymerases
poly
adp ribose
tricyclic inhibitors
tricyclic
Prior art date
Application number
MXPA02002138A
Other languages
English (en)
Inventor
Evan Webber Stephen
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Publication of MXPA02002138A publication Critical patent/MXPA02002138A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA02002138A 1999-08-31 2000-08-31 Inhibidores triciclicos de poli (adp-ribosa) polimerasas. MXPA02002138A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31
PCT/US2000/023882 WO2001016136A2 (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases

Publications (1)

Publication Number Publication Date
MXPA02002138A true MXPA02002138A (es) 2003-08-20

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002138A MXPA02002138A (es) 1999-08-31 2000-08-31 Inhibidores triciclicos de poli (adp-ribosa) polimerasas.

Country Status (48)

Country Link
US (1) US6548494B1 (es)
EP (1) EP1208104B1 (es)
JP (1) JP4272375B2 (es)
KR (1) KR20020038742A (es)
CN (1) CN1384835A (es)
AP (1) AP1553A (es)
AR (1) AR035162A1 (es)
AT (1) ATE287406T1 (es)
AU (1) AU781826B2 (es)
BG (1) BG106562A (es)
BR (1) BR0015051A (es)
CA (1) CA2382404C (es)
CO (1) CO5200769A1 (es)
CR (1) CR6577A (es)
CZ (1) CZ2002613A3 (es)
DE (1) DE60017575T2 (es)
DK (1) DK1208104T3 (es)
DO (1) DOP2000000069A (es)
DZ (1) DZ3216A1 (es)
EA (1) EA200200306A1 (es)
EC (1) ECSP003637A (es)
EE (1) EE200200100A (es)
ES (1) ES2234657T3 (es)
GE (1) GEP20043268B (es)
GT (1) GT200000145A (es)
HK (1) HK1045509B (es)
HR (1) HRP20020271A2 (es)
HU (1) HUP0202703A3 (es)
IL (1) IL147863A0 (es)
IS (1) IS6289A (es)
MA (1) MA25876A1 (es)
MX (1) MXPA02002138A (es)
MY (1) MY135910A (es)
NO (1) NO322475B1 (es)
NZ (1) NZ516793A (es)
OA (1) OA12016A (es)
PA (1) PA8501801A1 (es)
PE (1) PE20010538A1 (es)
PL (1) PL354242A1 (es)
PT (1) PT1208104E (es)
SI (1) SI1208104T1 (es)
SK (1) SK2592002A3 (es)
SV (1) SV2003000162A (es)
UA (1) UA73144C2 (es)
UY (1) UY26323A1 (es)
WO (1) WO2001016136A2 (es)
YU (1) YU15102A (es)
ZA (1) ZA200200830B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1374961A (zh) * 1999-09-28 2002-10-16 巴斯福股份公司 氮杂䓬吲哚衍生物,它们的制备和应用
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
WO2003051879A1 (en) * 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
ATE491703T1 (de) 2002-04-30 2011-01-15 Kudos Pharm Ltd Phthalazinonderivate
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
ATE404564T1 (de) 2003-01-09 2008-08-15 Pfizer Diazepinoindolderivate als kinaseinhibitoren
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
ATE454893T1 (de) * 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
CA2547077C (en) 2003-12-01 2015-11-03 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
KR100876520B1 (ko) * 2004-09-22 2008-12-31 화이자 인코포레이티드 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법
JP5201995B2 (ja) * 2005-01-19 2013-06-05 エーザイ インク． ジアザベンゾ［デ］アントラセン−３−オン化合物、及び、ｐａｒｐの阻害方法
CN101193892A (zh) 2005-06-14 2008-06-04 先灵公司 大环杂环天冬氨酰基蛋白酶抑制剂
WO2006137510A1 (ja) * 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. 脳血管障害時における出血低減剤
NZ587586A (en) * 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
US20080318999A1 (en) * 2005-08-05 2008-12-25 Methvin Isaac Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2038654A4 (en) * 2006-06-12 2010-08-11 Bipar Sciences Inc METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
WO2008030891A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CN101522609A (zh) * 2006-09-05 2009-09-02 彼帕科学公司 癌症的治疗
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
KR20100038295A (ko) 2007-06-05 2010-04-14 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 피질 카테콜아민성 신경 전달의 조정자로서의 이치환된 페닐피롤리딘
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
KR20100059950A (ko) 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체
CN101918003A (zh) * 2007-11-12 2010-12-15 彼帕科学公司 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌
CN101917982B (zh) * 2007-11-12 2013-03-20 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌
AU2008333786A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
AU2009212401A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating PARP-mediated diseases
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
BR112015004311A2 (pt) * 2012-09-05 2017-07-04 Bayer Cropscience Ag uso de benzodiazepinonas e benzazepinonas substituídas ou os sais das mesmas como substâncias ativas contra estresse abiótico de planta
WO2015103526A1 (en) * 2014-01-05 2015-07-09 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
CN108138177B9 (zh) 2015-07-23 2021-08-13 法国居里学院 Dbait分子与PARP抑制剂的组合用于治疗癌症的用途
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
KR20190107656A (ko) 2016-11-02 2019-09-20 이뮤노젠 아이엔씨 항체-약물 콘주게이트 및 parp 억제제로 병용 치료
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CA3096127A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
CR20200334A (es) 2018-01-05 2021-03-09 Cybrexa 1 Inc Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
US20200407720A1 (en) 2018-03-13 2020-12-31 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
KR20210025016A (ko) * 2018-06-28 2021-03-08 지앙수 헨그루이 메디슨 컴퍼니 리미티드 접합 삼중고리형 헤테로사이클 화합물과 그 치료 용도
WO2020038387A1 (zh) * 2018-08-24 2020-02-27 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
JP2022511540A (ja) * 2018-12-14 2022-01-31 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｓｔｉｎｇアゴニストとしての三環式化合物、ならびにその調製方法および医薬用途
JP2022541747A (ja) 2019-07-10 2022-09-27 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022021521A2 (pt) 2020-04-28 2023-01-24 Rhizen Pharmaceuticals Ag Compostos inovadores úteis como inibidores de poli(adp-ribose)polimerase (parp)
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
EP4274905A1 (en) 2021-01-08 2023-11-15 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
IL307339A (en) 2021-04-08 2023-11-01 Rhizen Pharmaceuticals Ag Poly(ADP-ribose) polymerase inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (es) 1964-03-24
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
KR100196356B1 (ko) 1993-09-28 1999-06-15 오스카 아끼히꼬 당뇨병 치료제
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
NZ313713A (en) * 1995-08-02 2001-03-30 Univ Newcastle Ventures Ltd Benzimidazole-4-carboxamide derivatives useful as poly(ADP-ribose)polymerase or PARP enzyme inhibitors
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
NZ501650A (en) 1997-05-13 2001-11-30 Octamer Inc Use of a pADPRT inhibitory compound that is not 3-aminobenzamide to treat inflammation and inflammatory diseases in mammals
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
AU9297998A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
JP2002515490A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド Ｐａｒｐ活性を抑制する縮合三環化合物

Also Published As

Publication number Publication date
DOP2000000069A (es) 2002-08-30
HUP0202703A3 (en) 2004-12-28
GEP20043268B (en) 2004-06-25
DK1208104T3 (da) 2005-05-02
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
MA25876A1 (fr) 2003-10-01
KR20020038742A (ko) 2002-05-23
SI1208104T1 (en) 2005-06-30
AU7338900A (en) 2001-03-26
OA12016A (en) 2006-04-19
SV2003000162A (es) 2003-07-29
PE20010538A1 (es) 2001-05-22
HUP0202703A2 (hu) 2002-12-28
DE60017575D1 (de) 2005-02-24
HK1045509B (zh) 2005-04-29
ATE287406T1 (de) 2005-02-15
GT200000145A (es) 2002-02-21
UA73144C2 (en) 2005-06-15
PL354242A1 (en) 2003-12-29
ZA200200830B (en) 2003-03-26
CA2382404A1 (en) 2001-03-08
EP1208104A2 (en) 2002-05-29
EA200200306A1 (ru) 2002-08-29
JP2003513015A (ja) 2003-04-08
BR0015051A (pt) 2002-06-25
CN1384835A (zh) 2002-12-11
CA2382404C (en) 2009-03-24
ES2234657T3 (es) 2005-07-01
CZ2002613A3 (cs) 2002-08-14
HK1045509A1 (en) 2002-11-29
JP4272375B2 (ja) 2009-06-03
ECSP003637A (es) 2002-03-25
HRP20020271A2 (en) 2005-12-31
NO20020421D0 (no) 2002-01-28
AR035162A1 (es) 2004-05-05
AP1553A (en) 2006-01-18
DE60017575T2 (de) 2005-06-09
DZ3216A1 (fr) 2001-03-08
EE200200100A (et) 2003-06-16
NO322475B1 (no) 2006-10-09
CO5200769A1 (es) 2002-09-27
SK2592002A3 (en) 2002-10-08
BG106562A (bg) 2003-03-31
CR6577A (es) 2003-12-05
MY135910A (en) 2008-07-31
UY26323A1 (es) 2001-04-30
NO20020421L (no) 2002-04-25
NZ516793A (en) 2004-03-26
EP1208104B1 (en) 2005-01-19
YU15102A (sh) 2004-12-31
PT1208104E (pt) 2005-04-29
WO2001016136B1 (en) 2001-11-15
AU781826B2 (en) 2005-06-16
IS6289A (is) 2002-02-27
WO2001016136A3 (en) 2001-06-21
IL147863A0 (en) 2002-08-14
PA8501801A1 (es) 2002-08-26

Similar Documents

Publication Publication Date Title
HK1045509A1 (en) Tricyclic inhibitors of poly(adp.ribose) polymerases.
NO20013313D0 (no) Tricykliske inhibitorer av poly(ADP-ribose) polymeraser
MXPA03001775A (es) Derivados de nucleosidos.
ZA200102318B (en) Use of glycogen phosphorylase inhibitors.
HK1034978A1 (en) Adenosine derivatives.
ITMI20002358A0 (it) Derivati di tieno [2,3-c]isochinolin-3-one come inibitori della poli(adp-ribosio)polimerasi
BR9915515B1 (pt) composiÇço curÁvel de multicomponentes.
MX237254B (es) Inhibidores sglt2 de glucosidos c-arilo.
ZA991975B (en) Enzyme inhibitors.
ID30132A (id) Turunan-turunan pirazol trisiklik
HK1051038A1 (en) Benzodiazepine derivatives.
HK1041407A1 (en) Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors.
TR199900853A3 (tr) Sübstitüe edilmis trisiklik bilesikler.
ZA991953B (en) Detection of fermentation-related microorganisms.
AU2001236791A1 (en) Systems for the prevention or treatment of carpal tunnel syndrome
HK1039124A1 (en) Phthalzaine derivatives phosphodiesterase 4 inhibitors.
NO20015062D0 (no) Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
AU4782499A (en) Substituted imidazo(1,2A)azines as selective inhibitors of COX-2
NO20004906D0 (no) PDE IV-inhiberende pyridinderivater
NO996080L (no) FremgangsmÕte for deteksjon, særlig av smÕ sjømÕl
DK1137438T3 (da) Præparat med forbedret terapeutisk rækkevidde, indeholdende nukleotidsynteseinhibitorer
HK1038009A1 (en) Tricyclic delta3-piperidines as pharmaceuticals.
WO2000064917A3 (en) Synthetic indolocarbazole regioisomers and uses thereof
NO20001569L (no) Bisetere av 1-oksa, aza og tianaftalen-2-oner som fosfolambaninhibitorer
ZA992106B (en) Statin-MMP inhibitor combinations.

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration